NCT02202031已完成不适用
Controlling Urgency Through Relaxation Exercises
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 161
- 试验地点
- 2
- 主要终点
- Change From Baseline in Frequency of Any Voiding or Incontinence Episodes Associated With At Least a Moderate Sensation of Urgency at 12 Weeks.
研究概览
简要总结
We propose to conduct a rigorous, 12-week, randomized controlled trial of two relaxation therapies in 160 ambulatory women who report an average of at least 3 urgency-associated voiding or incontinence episodes per day. Participants will be randomized in a 1:1 ratio to: 1) practice slowing their resting respiratory rate to 5 to 10 breaths per minute for at least 15 minutes/day at home using a portable guided-breathing device; or 2) use an identical-appearing device that plays relaxing music while monitoring their spontaneous breathing pattern. We do not know if either of the two types of relaxation therapies is effective in treating OAB. All women will also receive a usual care pamphlet providing basic information about other traditional self-management strategies for OAB.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Women aged 21 years or older who are able to walk to the bathroom without assistance
- •Report recurrent episodes of urgency (sudden or strong urges to urinate) beginning at least 3 months prior to screening
- •Able to record all voiding and incontinence episodes on a screening 3-day voiding diary29,30 and rate the severity of urgency associated with each episode using a validated urgency severity scale31
- •Document at least 9 voiding or incontinence episodes on the above 3-day voiding diary that are associated with at least moderate sensation of urgency (using the above validated urgency severity scale) 31
- •Willing to refrain from initiating other treatments that may affect voiding pattern during the trial period
排除标准
- •Use of anticholinergic OAB medications or other medications known to affect urinary function (i.e., diuretics, tricyclic antidepressants) within 1 month of screening
- •Current urinary tract infection (detected via screening dipstick urinalysis or urine culture) or a history more than 3 urinary tract infections in the preceding 1 year
- •Prior history of lower urinary tract surgery, pelvic cancer, or pelvic irradiation; or other pelvic or abdominal surgery within 6 months of screening
- •History of interstitial cystitis, fistula in the bladder or rectum, or congenital or childhood defect leading to chronic urinary incontinence, retention, or other chronic urinary symptoms
- •Known history of major neurologic conditions likely to have major or permanent effects on bladder function such as stroke, multiple sclerosis, spinal cord injury, or Parkinson's disease
- •Use of bladder botulinum injections, electrostimulation, or other invasive therapies for OAB or incontinence within 3 months of screening
- •Formal pelvic floor rehabilitation or other formal behavioral therapy for bladder symptoms involving a physical therapist or other certified practitioner within 3 months of screening
- •Started, stopped, or changed dosage of a psychoactive medication likely to affect anxiety (SSRIs/SNRIs, tricyclics) within 3 months of screening, or plans to start, stop, or change dosage during the trial
- •Resting blood pressure (average of 2 measures) less than 100/60 at screening (women with baseline low blood pressure may theoretically be at increased risk of hypotension with use of RESPeRATE)
- •Resting breathing rate already below 10 breaths/minute before treatment (as measured during run-in)
- •History of chronic pulmonary disease likely to interfere with breathing exercises (e.g., emphysema)
- •Currently pregnant, gave birth within the past 3 months, or planning pregnancy during the study period
- •Unable or willing to sign an informed consent, fill out questionnaires, or undergo study procedures
研究组 & 干预措施
Music Therapy
Experimental
Participants will use an identical appearing device, programmed to play quiet, relaxing music, while monitoring spontaneous breathing. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
干预措施: Music Therapy (Behavioral)
Paced Respiration
Experimental
Participants will use a small, commercially-available guided-breathing device to practice breathing at a rate slower than 10 breaths per minute. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
干预措施: Paced Respiration (Behavioral)
结局指标
主要结局
Change From Baseline in Frequency of Any Voiding or Incontinence Episodes Associated With At Least a Moderate Sensation of Urgency at 12 Weeks.
时间窗: Baseline to 12 weeks
Self-reported on voiding diary.
次要结局
- Change From Baseline in Frequency of Any Voiding or Incontinence Episodes Associated With a Severe Sensation of Urgency at 12 Weeks.(Baseline to 12 weeks)
- Change From Baseline Score of Urgency Severity and Impact Questionnaire (USIQ), Severity Subscale at 12 Weeks.(Baseline to 12 weeks.)
- Change From Baseline in Total Voiding Episodes at 12 Weeks.(Baseline to 12 weeks)
- Change From Baseline in Overactive Bladder Questionnaire Score at 12 Weeks(Baseline to 12 weeks.)
- Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Overall Sleep Quality Score at 12 Weeks.(Baseline to 12 weeks)
- Change From Baseline in Respiratory Sinus Arrhythmia (RSA) Change From Rest to Dot Task at 12 Weeks.(Baseline to 12 weeks)
- Change From Baseline in Pre-ejection Period (PEP) Change From Rest to Dot Task at 12 Weeks.(Baseline to 12 weeks)
- Change From Baseline in Urgency Incontinence Episodes at 12 Weeks.(Baseline to 12 weeks.)
- Change From Baseline in Urogenital Distress Inventory Short Form (UDI-6) Score at 12 Weeks.(Baseline to 12 weeks)
- Change From Baseline on Patient Perception of Bladder Condition (PPBC) Score at 12 Weeks.(Baseline to 12 weeks)
- Change From Baseline in Respiratory Sinus Arrhythmia (RSA) Change From Rest to Maze Task at 12 Weeks(Baseline to 12 weeks)
- Change From Baseline in Perceived Stress Scale (PSS) Score at 12 Weeks.(Baseline to 12 weeks)
- Change From Baseline in Respiratory Sinus Arrhythmia at 12 Weeks.(Baseline to 12 weeks)
- Change From Baseline in Respiratory Sinus Arrhythmia (RSA) Resting (Neutral) State at 12 Weeks.(Baseline to 12 weeks)
- Change From Baseline in Pre-ejection Period (PEP) Change From Rest to Maze Task at 12 Weeks(Baseline to 12 weeks)
- Change From Baseline in Center for Epidemiologic Studies Depression Scale (CES-D) Score at 12 Weeks.(Baseline to 12 weeks)
- Change From Baseline in Pre-ejection Period (PEP) Resting (Neutral) State at 12 Weeks.(Baseline to 12 weeks)
- Change From Baseline Score of Urgency Severity and Impact Questionnaire (USIQ), Health-Related Quality of Life Subscale at 12 Weeks.(Baseline to 12 weeks)
- Change From Baseline on Spielberger State Trait Anxiety Inventory (STAI) - Trait Component Score at 12 Weeks.(Baseline to 12 Weeks)
- Change From Baseline in Hospital Anxiety and Depression Scale (HADS) - Anxiety Subscale Score at 12 Weeks.(Baseline to 12 Weeks)
研究者
Alison Huang, MD
Assistant Professor
University of California, San Francisco
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Efficacy and Safety of Relaxin for the Treatment of Acute Heart FailureHeart Failure, CongestiveNCT00520806Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies1,161
Enrolling By Invitation
不适用
The Effect of Progressive Relaxation Exercises on Bariatric Surgery PeriodObesity, MorbidBariatric Surgery CandidatePostoperative PainAnxietyNCT05591898Başakşehir Çam & Sakura City Hospital72
已完成
不适用
Progressive Relaxation Exercises and Sleep, Anxiety and Stress in Risky PregnantsHealth Care Seeking BehaviorNCT05508542Cukurova University30
已完成
2 期
A study exploring the practicality and effectiveness of relaxation therapy plus autohypnotherapy for patients with breast and lung cancer undergoing radiotherapyung cancer, oesophageal cancer or breast cancerMalignant neoplasm of the lungCancerISRCTN89999034Hull and East Yorkshire Hospitals NHS Trust (UK)30
已完成
3 期
A Study to Compare Different Intubating Doses of Zemuron in Pediatric and Adolescent Subjects Under General AnesthesiaAnesthesiaNCT00124722Merck Sharp & Dohme LLC207